Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a median overall survival of 56 months in women with metastatic HER2-positive breast cancer.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
February 19, 2015
|
| In: |
The New England journal of medicine
Year: 2015, Volume: 372, Issue: 8, Pages: 724-734 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1413513 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1413513
|
| Author Notes: | Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil Ro, M.D., Vladimir Semiglazov, M.D., Mario Campone, M.D., Eva Ciruelos, M.D., Jean-Marc Ferrero, M.D., Andreas Schneeweiss, M.D., Sarah Heeson, B.Sc., Emma Clark, M.Sc., Graham Ross, F.F.P.M., Mark C. Benyunes, M.D., and Javier Cortés, M.D., for the CLEOPATRA Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1561017000 | ||
| 003 | DE-627 | ||
| 005 | 20230428162112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170719s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1413513 |2 doi | |
| 035 | |a (DE-627)1561017000 | ||
| 035 | |a (DE-576)491017006 | ||
| 035 | |a (DE-599)BSZ491017006 | ||
| 035 | |a (OCoLC)1340977634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Swain, Sandra M. |e VerfasserIn |0 (DE-588)1136982418 |0 (DE-627)893903809 |0 (DE-576)491013728 |4 aut | |
| 245 | 1 | 0 | |a Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer |c Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil Ro, M.D., Vladimir Semiglazov, M.D., Mario Campone, M.D., Eva Ciruelos, M.D., Jean-Marc Ferrero, M.D., Andreas Schneeweiss, M.D., Sarah Heeson, B.Sc., Emma Clark, M.Sc., Graham Ross, F.F.P.M., Mark C. Benyunes, M.D., and Javier Cortés, M.D., for the CLEOPATRA Study Group |
| 264 | 1 | |c February 19, 2015 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.07.2017 | ||
| 520 | |a In a randomized trial comparing pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel, the pertuzumab combination resulted in a median overall survival of 56 months in women with metastatic HER2-positive breast cancer. | ||
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 372(2015), 8, Seite 724-734 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer |
| 773 | 1 | 8 | |g volume:372 |g year:2015 |g number:8 |g pages:724-734 |g extent:11 |a Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa1413513 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170719 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 9 | ||
| 999 | |a KXP-PPN1561017000 |e 2974531946 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 19.07.2017"],"person":[{"role":"aut","family":"Swain","display":"Swain, Sandra M.","given":"Sandra M."},{"family":"Schneeweiss","role":"aut","display":"Schneeweiss, Andreas","given":"Andreas"}],"recId":"1561017000","name":{"displayForm":["Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D., Jungsil Ro, M.D., Vladimir Semiglazov, M.D., Mario Campone, M.D., Eva Ciruelos, M.D., Jean-Marc Ferrero, M.D., Andreas Schneeweiss, M.D., Sarah Heeson, B.Sc., Emma Clark, M.Sc., Graham Ross, F.F.P.M., Mark C. Benyunes, M.D., and Javier Cortés, M.D., for the CLEOPATRA Study Group"]},"language":["eng"],"origin":[{"dateIssuedDisp":"February 19, 2015","dateIssuedKey":"2015"}],"relHost":[{"name":{"displayForm":["Massachusetts Medical Society"]},"recId":"266889484","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1468837-2"],"eki":["266889484"],"issn":["1533-4406"]},"title":[{"title_sort":"New England journal of medicine","title":"The New England journal of medicine","subtitle":"NEJM"}],"origin":[{"publisher":"MMS ; MMS","dateIssuedDisp":"1928-","dateIssuedKey":"1928","publisherPlace":"Waltham, Mass. ; Boston, Mass."}],"part":{"text":"372(2015), 8, Seite 724-734","extent":"11","pages":"724-734","issue":"8","volume":"372","year":"2015"},"language":["eng"],"pubHistory":["198.1928 -"],"note":["Gesehen am 04.08.25"],"disp":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerThe New England journal of medicine","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"Massachusetts Medical Society","role":"isb"}],"titleAlt":[{"title":"NEJM"}]}],"physDesc":[{"extent":"11 S."}],"id":{"eki":["1561017000"],"doi":["10.1056/NEJMoa1413513"]},"title":[{"title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","title_sort":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a SWAINSANDRPERTUZUMAB1920 | ||